JB
FDMT icon

Julian Baker’s 4D Molecular Therapeutics FDMT Stock Holding History

Julian Baker’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-475,737
Closed -$3.57M – 87
2025
Q4 		$3.57M Buy
+475,737
New +$4.83M 0.02% 77
2024
Q2 		– Sell
-100,000
Closed -$3.19M – 98
2024
Q1 		$3.19M Buy
+100,000
New +$2.55M 0.04% 68

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Julian Baker's FDMT Position: Q1 2026 in Review

Julian Baker sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 475,737 shares — an estimated $3.57M sold.

Julian Baker first reported a position in FDMT in Q1 2024 and held it in 2 quarters. The position peaked at $3.57M in Q4 2025. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Julian Baker reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Julian Baker sold 475,737 4D Molecular Therapeutics shares in Q1 2026, an estimated $3.57M.
  • Julian Baker first reported a position in 4D Molecular Therapeutics in Q1 2024 and held it in 2 quarters.
  • Julian Baker's 4D Molecular Therapeutics position peaked at $3.57M in Q4 2025.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.